CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen
Abstract:SummaryAn increased basiliximab dose may saturate T-cell CD25 receptors in kidney transplant patients receiving calcineurin inhibitor (CNI)-free immunosuppression. In a 12-week study, 16 de novo kidney transplant patients were randomized to (i) 40 mg basiliximab with cyclosporine [n = 3] (controls), (ii) 80 mg basiliximab with cyclosporine [n = 6], or (iii) 80 mg basiliximab with everolimus (CNI-free) [n = 7], all with mycophenolic acid and steroids. Recruitment was stopped prematurely due to increased biopsy-… Show more
“…We performed sensitivity analysis excluding 2 trials [22, 35] that reported GFR estimates based on MDRD and a similar effect to the original meta analysis was observed (MD, 5.18; 95% CI, 2.07–8.30; I 2 , 56%). We performed additional sensitivity analysis excluding 2 trials [19, 24] that did not specify just which methods used to estimate GFR and a similar effect to the original meta analysis was observed (MD, 6.30; 95% CI, 3.06–9.53; I 2 , 42%).…”
Section: Resultsmentioning
confidence: 83%
“…After examining the titles and abstracts and eliminating identical publications, 67 possibly qualified articles were determined. Fifteen reports [22–36] of 11 trials, including a total of 1,633 randomized patients, were chosen for inclusion in the meta-analysis (Fig 1). One of these trials was available in abstract form only by Wolfgang et al 2012 [31].…”
Section: Resultsmentioning
confidence: 99%
“…GFR was estimated by Nankivell formula in 5 trails [24–27, 29–33], modification of diet in renal disease (MDRD) formula in 3 trails [22, 34, 35], and was unclear in 3 studies [23, 28, 36]. Early conversion to EVR (defined as ≤3 months after transplantation) was evaluated in 5 studies [22, 23, 25, 28, 30, 31], whereas 6 studies evaluated the late conversion to EVR [24, 26, 27, 31, 32–36]. There was a difference in baseline renal function, both within and between the trials, but most of the patients had mild or moderate renal dysfunction at the time of randomization.…”
Section: Resultsmentioning
confidence: 99%
“…There were 3 trials [23, 28, 31] that added to the meta-analysis examining the link between conversion from CNI to EVR and renal allograft loss while in the 5 other trials [22, 27, 30, 33, 35], no renal allografts were lost up to the first year posttransplantation. Patients converted to EVR had a similar risk of graft loss compared with the patients remaining on CNI (RR, 1.43; 95% CI, 0.44–4.68; I 2 , 37%; Fig 5).…”
BackgroundConversion to everolimus is often used in kidney transplantation to overcome calcineurin inhibitor (CNI) nephrotoxicity but there is conflicting evidence for this approach.ObjectivesTo investigate the benefits and harm from randomized clinical trials (RCTs) involving the conversion from CNI to everolimus after kidney transplantation.MethodsDatabases were searched up to March 2016. Two reviewers independently assessed trials for eligibility and quality, and extracted data. Results are expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI).ResultsEleven RCTs, with a total of 1,633 patients, met the final inclusion criteria. Patients converted to everolimus had improved renal function at 1 year posttransplant with an estimated glomerular filtration rate (eGFR) of 5.36 mL/min per 1.73 m2 greater than patients remaining on CNI (p = 0.0005) and the longer-term results (> 1 year) of renal function was identical to that of 1 year. There was not a substantial difference in graft loss, mortality, and the occurrence of adverse events (AEs) or serious AEs. However, the risks of acute rejection and trial termination due to AEs with everolimus are respectively 1.82 and 2.63 times greater than patients staying on CNI at 1 year posttransplant (p = 0.02, p = 0.03, respectively). Further, those patients who converted to everolimus had a substantially greater risk of anemia, hyperlipidemia, hypercholesterolemia, hypokalemia, proteinuria, stomatitis, mouth ulceration, and acne.ConclusionsConversion from CNI to everolimus after kidney transplantation is associated with improved renal function in the first 5 years posttransplant but increases the risk of acute rejection at 1 year posttransplant and may not be well endured.
“…We performed sensitivity analysis excluding 2 trials [22, 35] that reported GFR estimates based on MDRD and a similar effect to the original meta analysis was observed (MD, 5.18; 95% CI, 2.07–8.30; I 2 , 56%). We performed additional sensitivity analysis excluding 2 trials [19, 24] that did not specify just which methods used to estimate GFR and a similar effect to the original meta analysis was observed (MD, 6.30; 95% CI, 3.06–9.53; I 2 , 42%).…”
Section: Resultsmentioning
confidence: 83%
“…After examining the titles and abstracts and eliminating identical publications, 67 possibly qualified articles were determined. Fifteen reports [22–36] of 11 trials, including a total of 1,633 randomized patients, were chosen for inclusion in the meta-analysis (Fig 1). One of these trials was available in abstract form only by Wolfgang et al 2012 [31].…”
Section: Resultsmentioning
confidence: 99%
“…GFR was estimated by Nankivell formula in 5 trails [24–27, 29–33], modification of diet in renal disease (MDRD) formula in 3 trails [22, 34, 35], and was unclear in 3 studies [23, 28, 36]. Early conversion to EVR (defined as ≤3 months after transplantation) was evaluated in 5 studies [22, 23, 25, 28, 30, 31], whereas 6 studies evaluated the late conversion to EVR [24, 26, 27, 31, 32–36]. There was a difference in baseline renal function, both within and between the trials, but most of the patients had mild or moderate renal dysfunction at the time of randomization.…”
Section: Resultsmentioning
confidence: 99%
“…There were 3 trials [23, 28, 31] that added to the meta-analysis examining the link between conversion from CNI to EVR and renal allograft loss while in the 5 other trials [22, 27, 30, 33, 35], no renal allografts were lost up to the first year posttransplantation. Patients converted to EVR had a similar risk of graft loss compared with the patients remaining on CNI (RR, 1.43; 95% CI, 0.44–4.68; I 2 , 37%; Fig 5).…”
BackgroundConversion to everolimus is often used in kidney transplantation to overcome calcineurin inhibitor (CNI) nephrotoxicity but there is conflicting evidence for this approach.ObjectivesTo investigate the benefits and harm from randomized clinical trials (RCTs) involving the conversion from CNI to everolimus after kidney transplantation.MethodsDatabases were searched up to March 2016. Two reviewers independently assessed trials for eligibility and quality, and extracted data. Results are expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI).ResultsEleven RCTs, with a total of 1,633 patients, met the final inclusion criteria. Patients converted to everolimus had improved renal function at 1 year posttransplant with an estimated glomerular filtration rate (eGFR) of 5.36 mL/min per 1.73 m2 greater than patients remaining on CNI (p = 0.0005) and the longer-term results (> 1 year) of renal function was identical to that of 1 year. There was not a substantial difference in graft loss, mortality, and the occurrence of adverse events (AEs) or serious AEs. However, the risks of acute rejection and trial termination due to AEs with everolimus are respectively 1.82 and 2.63 times greater than patients staying on CNI at 1 year posttransplant (p = 0.02, p = 0.03, respectively). Further, those patients who converted to everolimus had a substantially greater risk of anemia, hyperlipidemia, hypercholesterolemia, hypokalemia, proteinuria, stomatitis, mouth ulceration, and acne.ConclusionsConversion from CNI to everolimus after kidney transplantation is associated with improved renal function in the first 5 years posttransplant but increases the risk of acute rejection at 1 year posttransplant and may not be well endured.
“…The absence of first-order elimination term lead to apparent VM and KM values that may be superior than "actual" values. In studies where KM was not identifiable, either KM value was fixed to low values,as done for brodalumab [77] (anti-IL-17R) and dupilumab [78] (IL-4Rα), with values of 0.02 and 0.01 mg/L, respectively, or the Michaelis-Menten term was replaced by a zero-order elimination rate constant, as done for cetuximab [79,80] and basiliximab [81] (anti-CD25). However, MichaelisMenten models allow a quantification of the relationship between antigen mass and pharmacokinetic parameters only if antigen mass is added as a covariate on Michaelis-Menten term parameters.…”
Therapeutic antibodies are increasingly used to treat various diseases, including neoplasms and chronic inflammatory diseases. Antibodies exhibit complex pharmacokinetic properties, notably due to the influence of antigen mass, i.e. the amount of antigenic targets to which the monoclonal antibody binds specifically. This review focuses on the influence of antigen mass on the pharmacokinetics of therapeutic antibodies quantified by pharmacokinetic modelling in humans. Out of 159 pharmacokinetic studies, 85 reported an influence of antigen mass. This influence led to nonlinear elimination decay in 50 publications which was described using target-mediated drug disposition (TMDD) or derived models, as quasi-steady-state, irreversible binding and Michaelis-Menten models. In 35 publications, the pharmacokinetics was apparently linear and the influence of antigen mass was described as covariate of pharmacokinetic parameters. If some reported covariates, such as circulating antigen concentration or tumor size, are likely to be correlated to antigen mass, others, such as disease activity or disease type, may contain little information on the amount of antigenic targets. In some cases, antigen targets exist in different forms, notably in the circulation and expressed at cell surface. The influence of antigen mass should be soundly described during the early clinical phases of drug development. To maximize therapeutic efficacy, sufficient antibody doses should be administered to ensure the saturation of antigen targets by therapeutic antibody in all patients. If necessary, antigen mass should be taken into account in routine clinical practice.
Key points-Current knowledge on the pharmacokinetics of monoclonal antibodies (mAbs) states that higher antigen amount was associated with mAb concentrations and higher mAb clearance. -Beacause of antigen mass, mAb pharmacokinetics may display nonlinear elimination shape. The influence of antigen mass on mAb pharmacokinetics is described using target-mediated drug disposition (TMDD) model, or approximations of this model. Antigen mass influence may be quantified using covariates. -Current mAb clinical development and use in clinical practice may be improved by optimization of dose, which should ensure the saturation of antigen targets in all patients.3
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.